Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date
2750 results found
2024 ∙ Rizzo, M. Gattino, S. Trombetta, T. Calandri, E. De Piccoli, N.
Psychosocial dimensions of vaccine hesitancy: A systematic review
All age groups Acceptance
Rating:
Not applicable
2024 ∙ de Fougerolles, T. R. Baissas, T. Perquier, G. Vitoux, O. Crepey, P. Bartelt-Hofer, J. Bricout, H. Petitjean, A.
Public health and economic benefits of seasonal influenza vaccination in risk groups in France, Italy, Spain and the UK: state of play and perspectives
Europe France Italy Spain United Kingdom All age groups Influenza Economic aspects
Rating:
Not applicable
2024 ∙ Olszewska, B. Zarycza Nowicki, R. J. Sokołowska-Wojdyło, M.
Rare COVID-19 vaccine side effects got lost in the shuffle. Primary cutaneous lymphomas following COVID-19 vaccination: a systematic review
Adults Older adults COVID-19 Safety
Rating:
Low
2024 ∙ Guo, J. Chen, X. Guo, Y. Liu, M. Li, P. Tao, Y. Liu, Z. Yang, Z. Zhan, S. Sun, F.
Real-world effectiveness of seasonal influenza vaccination and age as effect modifier: A systematic review, meta-analysis and meta-regression of test-negative design studies
All age groups Influenza Efficacy/effectiveness
Rating:
Critically low
2024 ∙ Yang, X. Shi, N. Liu, C. Zhang, J. Miao, R. Jin, H.
Relationship between vaccine hesitancy and vaccination behaviors: Systematic review and meta-analysis of observational studies
All age groups Parents/caregivers Acceptance
Rating:
Not applicable
2024 ∙ Nealon, J. Mefsin, Y. M. McMenamin, M. E. Ainslie, K. E. C. Cowling, B. J.
Reported effectiveness of COVID-19 monovalent booster vaccines and hybrid immunity against mild and severe Omicron disease in adults: A systematic review and meta-regression analysis
All age groups COVID-19 Efficacy/effectiveness Administration
Rating:
Critically low
2024 ∙ Mapindra, M. P. Mahindra, M. P. McNamara, P. Semple, M. G. Clark, H. Madsen, J.
Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy
Pregnant women Newborn RSV (Respiratory syncytial virus) Safety Efficacy/effectiveness
Rating:
Critically low
2024 ∙ Phijffer, Ewem de Bruin, O. Ahmadizar, F. Bont, L. J. Van der Maas, N. A. T. Sturkenboom, Mcjm Wildenbeest, J. G. Bloemenkamp, K. W. M.
Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes
Pregnant women RSV (Respiratory syncytial virus) Efficacy/effectiveness Safety
Rating:
High
2024 ∙ Srichawla, B. S. Fang, T. Kipkorir, V. Garcia-Dominguez, M. A.
Reversible cerebral vasoconstriction syndrome and posterior reversible encephalopathy syndrome following vaccination: analysis of the VAERS database and systematic review
Adults Older adults COVID-19 Measles Safety
Rating:
Critically low
2024 ∙ Vladulescu-Trandafir, A. I. Bojinca, V. C. Munteanu, C. Anghelescu, A. Popescu, C. Stoica, S. I. Aurelian, S. Balanescu, A. Baetu, C. Ciobanu, V. Onose, G.
Rheumatoid Arthritis and COVID-19 at the Intersection of Immunology and Infectious Diseases: A Related PRISMA Systematic Literature Review
All age groups COVID-19 Efficacy/effectiveness Safety
Rating:
Critically low
Loading...